Profile data is unavailable for this security.
About the company
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
- Revenue in DKK (TTM)24.63bn
- Net income in DKK3.19bn
- Incorporated1950
- Employees5.21k
- LocationH Lundbeck A/SOttiliavej 9VALBY 2500DenmarkDNK
- Phone+45 36301311
- Fax+45 36301940
- Websitehttps://www.lundbeck.com/
Mergers & acquisitions
| Acquired company | HLUN A:CPH since announced | Transaction value |
|---|---|---|
| Avadel Pharmaceuticals PLC | 1.69% | 2.25bn |
| Holder | Shares | % Held |
|---|---|---|
| Polar Capital LLPas of 31 Dec 2025 | 13.35m | 1.68% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 9.47m | 1.19% |
| JPMorgan Asset Management (UK) Ltd.as of 05 Feb 2026 | 9.05m | 1.14% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 8.00m | 1.00% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 6.92m | 0.87% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 5.47m | 0.69% |
| Artemis Investment Management LLPas of 30 Jan 2026 | 4.74m | 0.60% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 31 Dec 2025 | 4.63m | 0.58% |
| Folketrygdfondetas of 31 Dec 2024 | 4.41m | 0.55% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 4.23m | 0.53% |
